Gene therapy for tuberous sclerosis
US-2024343768-A1 · Oct 17, 2024 · US
Immunotherapy against several tumors including gastrointestinal and gastric cancer
US9717774B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9717774-B2 |
| Application number | US-201514615539-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2015 |
| Priority date | Mar 19, 2010 |
| Publication date | Aug 1, 2017 |
| Grant date | Aug 1, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70, wherein the peptide is capable of inducing T cells cross-reacting with said peptide, and wherein said peptide is not a full-length polypeptide, and wherein the peptide is in the form of a pharmaceutically acceptable salt. 2. The peptide according to claim 1 having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II. 3. The peptide according to claim 1 , wherein the peptide consists essentially of the amino acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70. 4. The peptide according to claim 1 , wherein the peptide is modified and/or includes non-peptide bonds. 5. The peptide according to claim 1 , wherein the peptide is a fusion protein comprising 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii) as derived from GenBank Accession Number X00497. 6. A peptide according to claim 1 for use in medicine. 7. The peptide of claim 1 , wherein said peptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70.
Assignees
Inventors
Classifications
wherein the target is cancer · CPC title
involving T-cells · CPC title
- A61K38/1709Primary
from mammals · CPC title
- C07K7/06Primary
having 5 to 11 amino acids · CPC title
Fusion polypeptide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9717774B2 cover?
- The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of …
- Who is the assignee on this patent?
- Immatics Biotechnologies Gmbh
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).